Evidence map›Paper›PMID 41728950›Full record

ArticleNucleic acids research2026

Isoform-specific single-cell perturb-seq reveals distinct functions of alternative promoters in drug response.

Helen E King, Savannah O'Connell, Daisy Kavanagh, Sofia Mason, Cerys McCool, Javier Fernandez-Chamorro, Christine L Chaffer, Susan J Clark, Helaine Graziele S Vieira, Timothy Sterne-Weiler and 1 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Helen E KingEMBL Australia, Garvan Institute of Medical Research, Sydney, 2010, New South Wales, Australia.
Savannah O'ConnellEMBL Australia, Garvan Institute of Medical Research, Sydney, 2010, New South Wales, Australia.
Daisy KavanaghEMBL Australia, Garvan Institute of Medical Research, Sydney, 2010, New South Wales, Australia.
Sofia MasonSt. Vincent Clinical School, University of New South Wales, Darlinghurst, 2010, New South Wales, Australia.
Cerys McCoolSt. Vincent Clinical School, University of New South Wales, Darlinghurst, 2010, New South Wales, Australia.
Javier Fernandez-ChamorroEMBL Australia, Garvan Institute of Medical Research, Sydney, 2010, New South Wales, Australia.
Christine L ChafferSt. Vincent Clinical School, University of New South Wales, Darlinghurst, 2010, New South Wales, Australia.
Susan J ClarkSt. Vincent Clinical School, University of New South Wales, Darlinghurst, 2010, New South Wales, Australia.
Helaine Graziele S VieiraEMBL Australia, Garvan Institute of Medical Research, Sydney, 2010, New South Wales, Australia.ORCID 0000-0002-1114-9439
Timothy Sterne-WeilerComputational Biology & Translation, Genentech, 9, South San Francisco, 94080, United States.
Robert J WeatherittEMBL Australia, Garvan Institute of Medical Research, Sydney, 2010, New South Wales, Australia.ORCID 0000-0003-3716-1783

Funding

Australian Research Council Discovery DP250103133Future Fellowship FT210100355Scrimshaw Foundation
6 · The paper itself

Abstract

CRISPR interference (CRISPRi) screens have emerged as powerful tools for dissecting gene function, yet their application to genes with multiple promoters, which comprise over 60% of human genes, remains poorly understood. Here, we demonstrate that CRISPR-dCas9-based screens exhibit widespread promoter specificity, with untargeted promoters often showing compensatory upregulation to maintain gene expression. Leveraging this selective targeting of individual promoters within the same gene, we developed Isoform-Specific single-cell Perturb-Seq to systematically analyse alternative promoter function. Our analysis revealed that alternative promoters in 51.6% of targeted genes drive distinct transcriptional programs. This suggests that promoter selection represents a fundamental mechanism for generating cellular diversity rather than mere transcriptional redundancy. In breast cancer models, this promoter-specific targeting revealed differential effects on drug sensitivity, where distinct estrogen receptor (ESR1) promoters showed opposing influences on tamoxifen response and patient survival. These findings demonstrate the necessity of promoter-level analysis in functional genomics and suggest new strategies for therapeutic intervention through promoter-specific targeting.

Indexed as

Breast NeoplasmsEstrogen Receptor alphaPromoter Regions, GeneticSingle-Cell AnalysisCell Line, TumorCRISPR-Cas SystemsFemaleGene Expression Regulation, NeoplasticHumansProtein IsoformsTamoxifenESR1 protein, humanEstrogen Receptor alphaProtein IsoformsTamoxifen

Identifiers

PMID41728950
PMCPMC12926921

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.